Cencora, Inc.
CORHealthcareNASDAQMedical Distribution
Scan Results
Daily timeframeCencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. With a market capitalization of $57.70B, it sits in large-cap territory.
Market Cap
$57.70B
Beta
0.58
P/E (TTM)
23.15
P/E (Fwd)
14.96
EPS (TTM)
$12.81
EPS (Fwd)
$19.82
ROE
107.1%
ROA
3.5%
Cash
$2.18B
Total Debt
$15.09B
Free CF
-$318.2M
52W Change
-0.4%
Annual Financials
Cash vs Debt
The company holds $2.18B in cash, though total debt stands at $15.09B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$318.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 107.1% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $238.59B (2022) to $321.33B (2025), reflecting a 35% increase over the period.
The relatively low beta of 0.58 suggests COR is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing COR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.